NanosonicsNNCSF 90 3-Year ROIIC % is 77.81 as of Jun. 2025, which is 296% above its 10-year median of 19.67. GuruFocus rates NNCSF with a GF Score™ of 90/100 and a GF Value™ of $3.56 (Modestly Undervalued). The stock has 1 warning sign investors should review. Among 800 Medical Devices & Instruments companies, Nanosonics ranks better than 87.62% on this metric.
3-Year Return on Invested Incremental Capital (3-Year ROIIC %) measures the change in earnings as a percentage of change in investment over 3-year.
Nanosonics's 3-Year ROIIC % for the quarter that ended in Jun. 2025 was 77.81%. High ROIIC is generally an indication that your business is capital efficient or has a higher operating leverage.
The industry rank for Nanosonics's 3-Year ROIIC % or its related term are showing as below:
NNCSF's 3-Year ROIIC % is ranked better than 87.62% of 800
companies
in the Medical Devices & Instruments industry
Industry Median: 1.285
vs NNCSF: 77.81
Return on Incremental Invested Capital (ROIIC) is an extension of Return on Investment Capital (ROIC). ROIC % tells investors how efficiently that profitability is earned per dollar of company capital. ROIIC narrows the focus even further and shows how profitable each additional unit of capital investment could be. ROIIC % is a more powerful metric than ROIC because it measures how much money the company can generate going forward on future capital investments.
High ROIIC is generally an indication that your business is capital efficient or has a higher operating leverage.
Be Aware
It's important to keep in mind that when tracking ROIIC, the metric is better suited to forecasting the trend of future returns rather than measuring current return on investment.
Nanosonics 3-Year ROIIC % Related Terms
Nanosonics 3-Year ROIIC % Historical Data
* Premium members only.
The historical data trend for Nanosonics's 3-Year ROIIC % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
NNCSF vs ISRG, BDX, MDLN: 3-Year ROIIC % Comparison
For the Medical Instruments & Supplies subindustry, Nanosonics's 3-Year ROIIC %, along with its competitors' market caps and 3-Year ROIIC % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Nanosonics 3-Year ROIIC % vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Nanosonics's 3-Year ROIIC % distribution charts can be found below:
* The bar in red indicates where Nanosonics's 3-Year ROIIC % falls into.
Nanosonics's 3-Year ROIIC % for the quarter that ended in Jun. 2025 is calculated as:
3-Year ROIIC %
=
3-Year Incremental Net Operating Profit After Taxes (NOPAT)**
/
3-Year Incremental Invested Capital**
=
( 5.3908647 (Jun. 2025) - -3.468 (Jun. 2022) )
/
( 65.47 (Jun. 2025) - 58.733 (Jun. 2022) )
=
8.8588647
/
6.737
=
131.50%***
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
** Annual data of NOPAT and Invested Capital was used to calculate 3-Year ROIIC %.
*** Please be aware that the ROIIC (Return on Invested Capital) calculations are based on company-level data using the primary share class. The calculated data provided is for demonstration purposes and may slightly differ from the results displayed in the title due to potential variations caused by currency exchange rate differences throughout the year.
Nanosonics (NNCSF) has a 3-Year ROIIC % of 77.81 as of Jun. 2025. 3-Year ROIIC % measures the change in earnings as a percentage of change in investment over 3-year. View historical data on Nanosonics and its competitors. This is 296% above median its historical median of 19.67. According to the industry distribution chart, Nanosonics ranks #99 out of 800 companies in the Medical Devices & Instruments industry, placing it in the top 12.4%.
Is Nanosonics' 3-Year ROIIC % too high?
Nanosonics' current 3-Year ROIIC % of 77.81 is 296% above median its 10-year median of 19.67. The Medical Devices & Instruments industry median 3-Year ROIIC % is 1.29. Nanosonics' value of 77.81 is 5955.3% above this industry median. Based on the distribution chart, Nanosonics ranks #99 out of 800 companies in the Medical Devices & Instruments industry, which is in the top quartile — a strong position relative to peers. Overall, Nanosonics has a GF Score™ of 90/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Nanosonics' 3-Year ROIIC % compare to ISRG and BDX?
According to the Medical Devices & Instruments industry distribution chart, Nanosonics ranks #99 out of 800 companies for 3-Year ROIIC %. This places Nanosonics in the top 12% of its industry — outperforming the majority of peers. The industry median 3-Year ROIIC % is 1.29. Nanosonics' value of 77.81 is 5955.3% above this benchmark. While the company's 10-year median is 19.67 vs. the industry median of 1.29, Nanosonics has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year ROIIC % for a Medical Devices & Instruments company?
The median 3-Year ROIIC % among Medical Devices & Instruments companies is 1.29, based on 800 companies in the industry. Companies in the top quartile (top 25%) have a 3-Year ROIIC % significantly above this median, while those in the bottom quartile fall well below. However, 3-Year ROIIC % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Nanosonics's current 3-Year ROIIC % of 77.81 is 5955.3% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year ROIIC % mean?
A high 3-Year ROIIC % can signal that a stock is expensive relative to its fundamentals. 3-Year ROIIC % measures the change in earnings as a percentage of change in investment over 3-year. View historical data on Nanosonics and its competitors. For the Medical Devices & Instruments industry, the median 3-Year ROIIC % is 1.29 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Nanosonics's current 3-Year ROIIC % is 77.81, which is 296% above median its own 10-year median of 19.67. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Nanosonics stock overvalued right now?
Based on GuruFocus' analysis, Nanosonics (NNCSF) is currently considered Modestly Undervalued. The stock's GF Value™ is $3.56, compared to a current price of $2.55 — trading 28.4% below its estimated fair value. The current 3-Year ROIIC % is 77.81, which is 296% above median its 10-year median of 19.67 and 5955.3% above the Medical Devices & Instruments industry median of 1.29. Nanosonics' overall GF Score™ is 90/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year ROIIC % calculated?
3-Year ROIIC % is calculated from a company's financial statements. For Nanosonics (NNCSF), the current 3-Year ROIIC % is 77.81 as of Jun. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Nanosonics (NNCSF) Overvalued in 2026?
Based on GuruFocus' analysis, Nanosonics stock appears to be undervalued.
The current stock price of $2.55 is trading 28.4% below its estimated GF Value™ of $3.56.
GuruFocus considers Nanosonics to be Modestly Undervalued.
Key valuation signals for NNCSF:
3-Year ROIIC %: 77.81 (296% above median its 10-year median of 19.67)
GF Value™: $3.56 vs. price of $2.55 (28.4% below fair value)
Industry Position: 5955.3% above the Medical Devices & Instruments median (#99 of 800)
No single metric tells the full story. See the NNCSF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Nanosonics is largely a single-product firm, and its Trophon device provides high-level disinfection of ultrasound probes used in semicritical procedures. The patented technology uses low-temperature sonically activated hydrogen peroxide mist suitable for probes sensitive to damage. Automated HLD is increasingly being used as the standard of care globally as it is superior in preventing cross-infection of patients. Nanosonics' revenue consists of capital sales of Trophon units, ongoing consumables sales, and service revenue. By December 2025, there were 38,000 Trophon units installed globally. Market penetration rates range from over 75% in Australia and New Zealand, over 50% in the US to single-digit penetration in Europe, Middle East, and Africa, and elsewhere in the Asia-Pacific region.
90GF Score
Get the complete analysis for NNCSF
3-Year ROIIC % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
NNCSF has been successfully added to your 
